Drug Repurposing of Anticancer Agents JP-8g and REDX05358 Against the Target Protein Plectin 1a in Epidemolysis Bullosa Simplex with Muscular Dystrophy (EBS-MD)

Year : 2025 | Volume : 03 | Issue : 02 | Page : 22 34
    By

    Fathima Abbas,

  1. Assistant Professor, Department of Microbiology, Al-Azhar College of Arts and Science, Thodupuzha, Kerela, India

Abstract

Epidermolysis Bullosa Simplex with Muscle Dystrophy is a genetic disease affecting the skin and muscles which can be seen at birth or start at adulthood due to the mutation in the protein Plectin 1a (PLEC gene) causing skin blisters and muscle weakness. This protein is seen in sarcolemma, Z disks in skeletal muscles, hemidesmosomes in skin and cardiac muscles giving stability to cytoskeleton, playing a crucial role in neuromuscular transmission but when get mutated it leads to lack of cytoskeleton support in connecting the intermediate filaments to microtubules, myosin and actin filaments. This research aims at treating this disease with two anticancer agents against the mutated plectin1a. Different bioinformatics tools are used to get the effectiveness of the two anticancer agents against the therapeutic target protein. Molecular docking between the drugs and target in PyRx screening software and further visualization of those interactions in BIOVIA Discovery Studio are done. SwissADME tool evaluated the pharmacological properties of the drugs. Three ligand molecules JP-8g, REDX05358 and CAY10736 were selected for molecular docking with high negative binding affinity (least binding affinity) and pharmacological properties of two were studied. Anticancer agents JP-8g and REDX05358 are finally selected for drug repurposing against the mutated plectin 1a in EBS-MD as they give good molecular docking score and good ADME properties

Keywords: Epidermolysis Bullosa Simplex with Muscular Dystrophy (EBS-MD), plectin 1a acting binding domain, ligands, JP-8g, REDX05358, PyRx, molecular docking, BIOVIA, ADME

[This article belongs to International Journal of Cell Biology and Cellular Functions ]

How to cite this article:
Fathima Abbas. Drug Repurposing of Anticancer Agents JP-8g and REDX05358 Against the Target Protein Plectin 1a in Epidemolysis Bullosa Simplex with Muscular Dystrophy (EBS-MD). International Journal of Cell Biology and Cellular Functions. 2025; 03(02):22-34.
How to cite this URL:
Fathima Abbas. Drug Repurposing of Anticancer Agents JP-8g and REDX05358 Against the Target Protein Plectin 1a in Epidemolysis Bullosa Simplex with Muscular Dystrophy (EBS-MD). International Journal of Cell Biology and Cellular Functions. 2025; 03(02):22-34. Available from: https://journals.stmjournals.com/ijcbcf/article=2025/view=229176


References

  1. Uitto J, Pulkkinen L, Smith FJ, McLean WI. Plectin and human genetic disorders of the skin and muscle: The paradigm of epidermolysis bullosa with muscular dystrophy. Exp Dermatol. 1996 Oct;5(5):237–46.
  2. Kyrova J, Kopeckova L, Buckova H, Mrazova L, Vesely K, Hermanova M, et al. Epidermolysis bullosa simplex with muscular dystrophy. Review of the literature and a case report. J Dermatol Case Rep. 2016 Nov 11;10(3):39.
  3. Niemi KM, Sommer H, Kero M, Kanerva L, Haltia M. Epidermolysis bullosa simplex associated with muscular dystrophy with recessive inheritance. Arch Dermatol. 1988 Apr 1;124(4):551–4.
  4. Shimizu H, Takizawa Y, Pulkkinen L, Murata S, Kawai M, Hachisuka H, et al. Epidermolysis bullosa simplex associated with muscular dystrophy: Phenotype-genotype correlations and review of the literature. J Am Acad Dermatol. 1999 Dec 1;41(6):950–6.
  5. Pfendner E, Rouan F, Uitto J. Progress in epidermolysis bullosa: The phenotypic spectrum of plectin mutations. Exp Dermatol. 2005 Apr;14(4):241–9.
  6. Charlesworth A, Chiaverini C, Chevrant‐Breton J, DelRio M, Diociaiuti A, Dupuis RP, et al. Epidermolysis bullosa simplex with PLEC mutations: New phenotypes and new mutations. Br J Dermatol. 2013 Apr 1;168(4):808–14.
  7. Chiaverini C, Charlesworth A, Meneguzzi G, Lacour JP, Ortonne JP. Epidermolysis bullosa simplex with muscular dystrophy. Dermatol Clin. 2010 Apr 1;28(2):245–55.
  8. Winter L, Wiche G. The many faces of plectin and plectinopathies: Pathology and mechanisms. Acta Neuropathol. 2013 Jan;125:77–93.
  9. Gostyńska KB, Nijenhuis M, Lemmink H, Pas HH, Pasmooij AM, Lang KK, et al. Mutation in exon 1a of PLEC, leading to disruption of plectin isoform 1a, causes autosomal-recessive skin-only epidermolysis bullosa simplex. Hum Mol Genet. 2015 Jun 1;24(11):3155–62.
  10. Castanón MJ, Walko G, Winter L, Wiche G. Plectin–intermediate filament partnership in skin, skeletal muscle, and peripheral nerve. Histochem Cell Biol. 2013 Jul;140:33–53.
  11. Fuchs P, Zörer M, Rezniczek GA, Spazierer D, Oehler S, Castañón MJ, et al. Unusual 5′ transcript complexity of plectin isoforms: novel tissue-specific exons modulate actin binding activity. Hum Mol Genet. 1999 Dec 1;8(13):2461–72.
  12. Sousa SF, Fernandes PA, Ramos MJ. Protein–ligand docking: Current status and future challenges. Proteins. 2006 Oct 1;65(1):15–26.
  13. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, Rodgers JR, et al. The Protein Data Bank: A computer-based archival file for macromolecular structures. J Mol Biol. 1977 May 25;112(3):535–42.
  14. Chang CE, Chen W, Gilson MK. Ligand configurational entropy and protein binding. Proc Natl Acad Sci USA. 2007 Jan 30;104(5):1534–9.
  15. Gilson MK, Given JA, Bush BL, McCammon JA. The statistical-thermodynamic basis for computation of binding affinities: A critical review. Biophys J. 1997 Mar 1;72(3):1047–69.
  16. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009 Jul 1;37(Suppl_2):W623–33.
  17. Sargsyan K, Grauffel C, Lim C. How molecular size impacts RMSD applications in molecular dynamics simulations. J Chem Theory Comput. 2017 Apr 11;13(4):1518–24.
  18. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014 Jan;32(1):40–51.
  19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
  20. Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem. 2008 Mar 14;3(3):435–44.
  21. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010 Apr 8;53(7):2719–40.
  22. Sun Y, Liu J, Sun T, Zhang X, Yao J, Kai M, et al. Anti-cancer small molecule JP-8g exhibits potent in vivo anti-inflammatory activity. Sci Rep. 2014 Mar 14;4(1):4372.
  23. Jiang X, Sun Y, Yao J, Cao Y, Kai M, He N, et al. Core scaffold‐inspired concise synthesis of chiral spirooxindole‐pyranopyrimidines with broad‐spectrum anticancer potency. Adv Synth Catal. 2012 Mar 16;354(5):917–25.
  24. Mason H, Scrace S, Testar R, Rainard J, Talab F, Poonawala R, et al. Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors. Cancer Res. 2017 Jul 1;77(13_Suppl):5160.
  25. Turner N, Zeng XY, Osborne B, Rogers S, Ye JM. Repurposing drugs to target the diabetes epidemic. Trends Pharmacol Sci. 2016 May 1;37(5):379–89.
  26. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014 May 1;19(5):637–46.
  27. Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, et al. Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat. 2020 Sep 1;52:100713.
  28. March-Vila E, Pinzi L, Sturm N, Tinivella A, Engkvist O, Chen H, et al. On the integration of in silico drug design methods for drug repurposing. Front Pharmacol. 2017 May 23;8:298.
  29. Osmanagic-Myers S, Wiche G. Plectin-RACK1 (receptor for activated C kinase 1) scaffolding: A novel mechanism to regulate protein kinase C activity. J Biol Chem. 2004 Apr 30;279(18):18701–10.
Regular Issue Subscription Original Research
Volume 03
Issue 02
Received 16/05/2025
Accepted 04/07/2025
Published 23/08/2025
Publication Time 99 Days
43

Login


My IP

PlumX Metrics